March 2024
Core topics in this month’s edition include:
- Jubbonti (denosumab-bbdz) – new first-time interchangeable biosimilar approval
- Rezdiffra (resmetirom) – new drug approval
- Wegovy (semaglutide) – new indication
- Wyost (denosumab-bbdz) – new first-time interchangeable biosimilar approval